Amgen Highlights MariTide’s Potential in Obesity and T2D

At the 2026 J.P. Morgan Healthcare Conference, Amgen CEO Robert Bradshaw highlighted positive mid-stage data for MariTide (maridebart cafraglutide), its investigational GLP-1/GIP dual agonist for obesity and type 2 diabetes (T2D).

In Phase II trials (NCT05669599, NCT06660173), MariTide demonstrated strong efficacy in chronic weight management on monthly and quarterly dosing, and in T2D, once-monthly dosing led to meaningful reductions in HbA1c and body weight after 24 weeks. Patients also showed improvements in cardiometabolic parameters, with a safety profile consistent with the GLP-1RA class, mostly mild-to-moderate gastrointestinal events.

Amgen is now running six global Phase III studies and preparing a late-stage T2D trial. Bradshaw emphasized MariTide’s differentiated dosing and long-term maintenance potential as a competitive advantage versus current GLP-1RAs.

The obesity and T2D markets remain competitive, with Novo Nordisk and Eli Lilly advancing both injectable and oral GLP-1 therapies. Global obesity sales are projected to reach $173.5bn by 2031.

19-01-2026